EPCAM and neoplasm: We observed a statistically lower proportion of EpCAM and CD56 expression on tumor cells in patients with NSCLC than those with SCLC (respectively, 70.1 vs. 87.5%, p = 0.0004, and 60.4 vs. 88.5%, p = 0.0112).